MIRA INFORM REPORT

 

 

Report Date :

01.12.2011

 

IDENTIFICATION DETAILS

 

Name :

TABROS PHARMA

 

 

Registered Office :

Essa House, 32-1/C, Block-6, P.E.C.H.S., Karachi

 

 

Country :

Pakistan

 

 

Year of Establishment :

1971

 

 

Legal Form :

Proprietorship

 

 

Line of Business :

Manufacture & Marketing of Pharmaceutical Products

 

 

No. of Employees :

207 persons

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – September 30, 2011

 

Country Name

Previous Rating

(30.06.2011)

Current Rating

(30.09.2011)

Pakistan

B2

B2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

NOTE:

We wish to inform you that Arfeen International (Pvt) Limited and Tabros Pharma are two separate companies and does not belong to the same group.

 

 

Business Name

 

TABROS PHARMA

 

 

Full Address       

 

Registered Address

Essa House, 32-1/C, Block-6, P.E.C.H.S., Karachi, Pakistan

                       

Tel #

92 (21) 34533418, 34533416

Fax #

92 (21) 34532898

Email

tabroz@super.net.pk

           

 

Short Description Of Business

 

a.

Nature of Business        

Manufacture & Marketing of Pharmaceutical Products

b.

Year Established

1971

c.

National Tax #

0277826

 

Factory Location

           

Address

L-20/B, Sector-22, Federal B Industrial Area, Karachi, Pakistan

Tel #

92 (21) 36360631, 36366789

Fax #

92 (21) 36365425

 

 

Legal Status

 

Subject Company was established as a Proprietorship business in 1971

 

 

Details of Proprietor

 

Names

Nationality

Address

Occupation

Designation

Mr. Muhammad Abdullah Essa

Pakistani

 

 

Essa House, 32-1/C, Block-6, P.E.C.H.S., Karachi, Pakistan

Business

 

 

Proprietor

 

 

 

Associates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

 

A.         Subsidiary

 

                        None                                             

           

B.         Associated Companies

 

            - Do -

 

 

Products

 

(1) Subject Company is engaged in manufacture & marketing of Pharmaceutical Products by its brand names of AMYGRA, ARIX, ARTEMAL, CALIX, CEFON, DURAGESIC, DURAZANIL, E-CLAR, FENAC, FERRY, FERRY-F, FIXITIL, FIXITIL-T, FLENCH, FOCIN, FUSIL, FUSIL-B, FUSIL-HC, G-MET, GAVEL, HEMSAMIC, KLIC, KLIC-F, METEOSPASMYL, OPTIMOL, ORIBRO, ORPHINE, PANTONIL, PECTUS, PROGREL, RONIL, RUMOLON, RUMOLON INJ, SPADIX, TABROMIDE, TABROPHAGE, TABROXACIN, TONICARD, V-PAN, VADIL, VIZOR, ZATRON, ZEEST, ZISCAR.

 

(2)   It purchases raw material against D/A, D/P basis.

 

(3)   Its mainly import from China, India & European Countries.

 

(4) Its’ major customers are Distributors, Traders, Pharmacies & Hospitals located at all major cities of Pakistan.

 

(5) Subject operates from caption leased office & factory premises situated at commercial & industrial area of Karachi.

 

(6)  Subject employs about 207 persons in its set up.

 

 

Annual Sales Volume

 

Year
In Pak Rupees

2010

450,000,000/- (Estimated)

 

 

Capacity & Production

           

The capacity and production of the company’s plant is indeterminable as it is multi- product and involves various processes of manufacture.

Trade Suppliers (Foreign)

 

(1)     DAFRA PHARMA, BELGIUM.

(2)     INTER HEALTH, U.S.A.

(3)     LONZA, SWITZERLAND.

(4)     MAYOLY SPINDLER, FRANCE.

(5)     UNIBIOS, ITALY.

(6)     ALCON PHARMACEUTICALS, INDIA.

(7)     NAN YA PLASTIC CORPORATION, SINGAPORE.

 

 

Bankers

 

(1) Faysal Bank Limited, Pakistan.

(2) Soneri Bank Limited, Pakistan.

(3) Habib Metropolitan Bank Limited, Pakistan.

(4) Standard Chartered Bank, Pakistan.

(5) Faysal Bank Limited, Pakistan.

 

 

Memberships

 

·         Karachi Chamber of Commerce & Industry.(KCCI)

·         Pakistan Pharmaceutical Manufacturers Association.(PPMA)

 

 

Foreign Exchange Rates

 

Currency

 

Unit

Pakistani Rupee

US Dollar

1

           Rs. 87.50

UK Pound

1

           Rs. 136.30

Euro

1

           Rs. 116.70

 

 

Comments

 

Subject Company was established in 1971 and is engaged in manufacture & marketing of Pharmaceutical Products. Market reputation is good. Trade relations are reported as fair. Subject can be considered for normal business dealings at usual trade terms and conditions.

 

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.52.16

UK Pound

1

Rs.81.29

Euro

1

Rs.69.47

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.